Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine and CBT4CBT for Post-taper Relapse in MAT
NCT03547622Phase 1Completed
- Sponsor
- Yale University
- Start
- May 2018
- Primary completion
- Feb 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid use disorder (OUD) comparing MAT taper with galantamine with MAT taper with placebo (2 arms). Primary endpoint: Change in Methadone/Buprenorphine Dose to 0 mg for Successful Completion of Taper. Started May 2018; status: completed.
02
Drugs
galantamine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03547622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547622.